Clinical analysis of malignant lymphoma secondary to transplantation: the notorious lymphoproliferative disease.

Zhimin Yan, Hao Wang, Yanquan Liu, Yue Yin, Mingfeng Zhao

Abstract readCase Reports

In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhimin YanDepartment of Hematology, The First Central Clinical College, Tianjin Medical University Tianjin 300380, China.

Hao WangDepartment of Hematology, The First Central Clinical College, Tianjin Medical University Tianjin 300380, China.

Yanquan LiuDepartment of Hematology, The First School of Clinical Medicine, Guangdong Medical University Dongguan 523808, Guangdong, China.

Yue YinDepartment of Hematology, Fujian Medical University Union Hospital Fuzhou 350001, Fujian, China.

Mingfeng ZhaoDepartment of Hematology, Tianjin First Central Hospital Tianjin 300380, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As one of the worst complications after solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT), post-transplant lymphoproliferative disorder (PTLD) usually progresses rapidly and accompanies with a high mortality rate, which is the most notorious adverse event threatening long-term survival of organ transplant recipients. PTLD is generally characterized by malignant clonal proliferation of lymphocytes, so the location of the disease is uncertain, the clinical symptoms and signs are very complex, lack of specificity, and it is easy to miss diagnosis and misdiagnosis in clinical practice, which will lead to low survival of patients after transplantation. To this end, the clinical data of two patients with PTLD were retrospectively studied, and characteristics of medical history, clinical manifestations, treatment process, curative effect and prognosis of the patients with PTLD were systematically analyzed and discussed, with a view to improving the novel understanding of PTLD in the field of hematology and oncology.

Indexed as

differential diagnosisextranodal lymphomaorgan transplantationPost-transplant lymphoproliferative disorderprognosis

Identifiers

PMID38074803

PMCPMC10703646

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.